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Abstract 
 
Autism spectrum disorder (ASD) is a heterogeneous 
neurodevelopmental disorder that has been confirmed 
to be related to some genetics risk factors which can 
lead to different clinical phenotypes. At present, ASD is 
mainly diagnosed based on some behavior and 
cognitive scales, which can not reveal the mechanism 
of disease occurrence, development and prognosis. In 
recent years, some studies have applied omics 
techniques into ASD research, but these studies are 
only based on single omics data source such as 
genomics, proteomics or transcriptomic without 
investigating ASD subtypes from integration of multi-
omics data. In this study, we proposed an ASD 
subtyping framework that integrates clinical and multi-
omics data to identify and analyze ASD subtypes at the 
molecular level. Due to the heterogeneity of different 
data modalities, a fusion clustering strategy was used 
to produce more accurate and interpretable clusters. 
Based on ASD subtyping results, we also proposed a 
classification framework to predict the subtype of new 
ASD patients. Deep learning method was used to 
extract features from each data modality, then all 
extracted features were integrated by the multiple 
kernel learning method to improve the classification 
accuracy.  
 
1. Introduction  
 
Autism Spectrum Disorder (ASD) is a 
neurodevelopmental disorder characterized by 
impaired communication and social interaction as well 
as restricted and repetitive interests and behaviors [1]. 
ASD is now diagnosed mainly based on Diagnostic 
and Statistical Manual of Mental Disorders, Fifth 
Edition (DSM-5) criteria and various behavior scales 
such as Autism Diagnostic Observation Schedule 
(ADOS) , Autism Diagnostic Interview, Revised (ADI-
R) [2]. However, this behavior-based diagnosis method 
does not define any subtypes that can reflect 
phenotypic heterogeneity of ASD and facilitate better 
understanding of etiology of the condition. In recent 
years, some ASD subtyping studies based on clinical 
manifestation or behavioral symptoms have emerged 
[3, 4], but the symptoms on ASD patients change 
significantly with the increase of age, resulting in 
subjective and unreliable subtyping results that are also 
difficult to elucidate the etiology of each ASD 
phenotype. With the wide application of artificial 
intelligence on medical image analysis, a large body of 
research has emerged using multiple Magnetic 
Resonance Imaging (MRI) techniques finding impaired 
functional and structural connectivity between brain 
regions. And these abnormalities in connectivity 
sometimes can be used as biomarkers for the diagnosis 
of ASD in clinic. 
However, the biomarkers obtained in these imaging 
studies are not always consistent, making it impossible 
to achieve clinical reliability by relying only on 
medical imaging [5, 6]. The reason for this 
inconsistence is that each ASD subtype has its distinct 
characterizations in brain, while most imaging studies 
do not take into account the heterogeneity between 
different ASD subtypes. So if considering patient 
subtypes in imaging analysis, it can improve the 
reliability of ASD clinical diagnosis and treatment. At 
present, there are studies explaining the imaging 
heterogeneity of ASD patients from molecular 
perspective. For example, Qureshi et al found that 
16p11.2 chromosome deletion leads to an increase in 
brain volume, while its duplication leads to a decrease 
in brain volume [7]. Some studies also revealed how 
ASD risk genes (such as CNTNAP2, MET) affect 
brain structure and function networks [8, 9]. These 
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studies have emphasized the important role of 
inheritability in ASD diseases. And combining genes 
and imaging can facilitate the discovery of more 
accurate ASD imaging biomarkers. 
Behavioral assessment and imaging diagnosis both 
have certain limitations and neither one can reveal the 
etiology of ASD. With the continuous advancement in 
basic scientific research especially in the fields of 
genetics and neuroscience, researchers have 
determined that ASD is a kind of diffuse 
developmental disorder of the central nervous system 
caused by a variety of environmental factors under the 
influence of certain genetic factors. In 2009, the NIMH 
conducted a research project called Research Domain 
Criteria (RDoC) [10], which aims to transcend the 
limits of traditional classification method, combining 
genetics, neuroscience, behavioral science and other 
methods to clarify the neural basis and biomarkers of 
mental illness. This project implies that we can find 
more clinically relevant ASD subtypes and biomarkers 
by integrating multiple data sources such as genetic, 
neuroimaging, behavioral assessment, and patient 
clinical history to achieve personalized healthcare and 
improved prognosis for patients with ASD. 
In the past few decades, scientists have been 
actively exploring the genetic basis of ASD using 
methods such as cytogenetic research, linkage analysis, 
and association analysis of candidate genes [11]. The 
findings show that ASD is a complex disease with high 
level of genetic heterogeneity. In recent years, great 
progress has been made in the identification of ASD 
genetic pathogenicity loci. At present, there are 
hundreds of pathogenic genes associated with ASD, 
most of which are rare and have various types of 
mutations [12]. In addition to the mutations inherited 
from parents, many ASD de novo mutations have been 
discovered by using the whole-exome sequencing 
technique, and the number of identified mutations is up 
to more than 1000 [13]. Iossifov et al. used whole-
exome sequencing find that in a family with only one 
ASD patient, new gene mutations such as copy number 
variant (CNV) accounted for approximately 30% of 
ASD cases [14]. Common genetic variants such as 
single nucleotide polymorphism (SNP) also influence 
the onset of ASD. Although many ASD-related 
pathogenic genes have been found, the high level of 
inheritance heterogeneity is far from explaining the 
pathogenesis of ASD. Transcriptomics studies use 
cDNA microarrays and high-throughput RNA 
sequencing technology to obtain gene expression data, 
combining with gene co-expression network analysis 
to discover the molecular mechanisms related to ASD 
[15, 16]. Proteomics studies have found that the 
clinical manifestations of ASD may be related to 
changes in proteins, such as mutations leading to 
changes in protein and amino acid sequences, and 
mutations in gene regulatory regions leading to 
changes in protein expression or abnormal 
modification of proteins [17, 18]. In recent years, the 
acquisition of specific biomarkers through 
metabolomics research is effective for early ASD 
screening and diagnosis. Currently, some analytical 
techniques such as gas chromatography-mass 
spectrometry (Gc-Ms), capillary electrophoresis-time-
of-flight mass spectrometry (CE-TOF), liquid 
chromatography-mass spectrometry (Lc-Ms), nuclear 
magnetic resonance (NMR) have been widely used in 
ASD urine or blood metabolite analysis. By 
comparison with the healthy controls, the significant 
differences in metabolites are mainly related to 
intestinal microbial metabolism, energy metabolism, 
oxidative stress [19-21]. At present, it has been found 
that ruminococcus, clostridium and desulfovibrio in the 
gastrointestinal tract of ASD are significantly different 
from healthy controls [22, 23]. The damage to normal 
nerve development caused by gastrointestinal 
microflora and its metabolites is one of the ASD 
etiology research directions. Through bacterial tag-
encoded FLX amplicon pyrosequencing (bTEFAP) 
technique, DNA is directly extracted from feces of 
ASD patients for sequencing to determine specific 
bacterial composition, and then all microorganisms in 
the intestine can be identified [24]. 
In summary, most of the above studies are based on 
single omics data source and did not systematically 
analyze and explore ASD subtypes. The 
characterization of each omics technique on ASD 
subtype level has not yet been studied as well as the 
interaction between different omics data and their 
distinct regulatory role on signaling pathways. To 
solve this problem, we proposed an ASD subtyping 
framework by fusing multi-omics and clinical 
assessment data using the unsupervised clustering 
method. Then for subtype prediction of a new 
unknown patient, we proposed a classification 
framework based on the multi-omics data and 
clustering results. Due to the complexity and high 
dimensionality of omics data, deep learning method 
was used to automatically extract discriminative 
features from all omics data. Then we used the 
multiple kernel learning (MKL) method to explore 
complementary information among these features and 
discover different contribution of relevant omics 
features.  
 
2. ASD subtyping based on multi-omics 
data  
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Studies have shown that ASD is highly heritable, 
and that each ASD-related gene mutation or CNV will 
result in a different clinical phenotype. However, due 
to the etiology complexity of ASD, it is generally 
possible to find pathogenic genes distributed on 
different chromosomes in patients. At the same time, 
due to the difference in gene expression and the 
interaction of multiple genes in a common path, ASD 
appears in clinical phenotype with high level of 
heterogeneity. Therefore, we propose an ASD 
subtyping framework by integrating clinical and multi-
omics data to discriminate among distinct ASD 
subtypes. 
Cluster analysis is a major analytical method for 
disease subtypes based on high-dimensional omics data. 
It can classify functionally related genes (or other 
omics data) according to the consistent trend or 
proximity of expression levels. It has already been 
widely used in cancer subtyping [25]. Cluster analysis 
generally needs to establish an accurate measure of the 
"distance" between samples. The measurement 
methods include Euclidean distance, Chebyshev 
distance, Manhattan distance, Minkowski distance, 
angle cosine, Pearson correlation coefficient and so on. 
Since the clustering results are susceptible to a large 
amount of noise in the omics data, and the omics data 
is usually very high in dimension, it is necessary to use 
data dimensionality reduction methods before cluster 
analysis such as Principal Component Analysis (PCA) , 
Partial Least Square (PLS), etc. removing data 
containing useless information. In the field of 
bioinformatics analysis, common clustering algorithms 
include Hierarchical Clustering, K-means, Fuzzy C-
means, and Self- Organizing Maps and so on. 
The above cluster analysis methods are mainly 
based on the statistical theory that the knowledge in the 
biological field is rarely used, so that the clustering 
result does not produce the reasonable biological 
interpretation that people need to understand the 
disease. In addition, it is more important to combine 
and fuse different kind of omics data effectively for 
clustering. The easiest way is to concatenate feature 
matrix of each omics data source directly, but this 
approach will result in a further lower signal-to-noise 
ratio. Another way is to cluster individually for each 
omics data source and then merge the clustering results. 
However, the potential inconsistencies between each 
clustering results may cause merge errors. Currently, 
there are two methods for the fusion clustering of 
different genomics data in the field of tumor research, 
including the iCluster [26] method based on the joint 
latent variable model and the SNF [27] method based 
on the sample similarity network. Studies have shown 
that SNF has better performance in tumor subtyping 
than iCluster [27]. 
In ASD subtyping, we can also use the above two 
methods to perform fusion cluster analysis on various 
omics data (such as gene expression, protein 
expression, etc.) and compare the different 
performance between the two methods. Since cluster 
analysis is an unsupervised learning method, its 
clustering results can not be tested by ground truth. 
The biostatistical method can be used to perform 
statistical tests on clustering results, including survival 
analysis, contour coefficients and clustering statistical 
significance test. The multi-omics based ASD 
subtyping framework is shown in Figure 1. 
 
 
 
Figure 1. Framework of multi-omics based 
ASD subtyping 
 
3. Subtype prediction of new ASD patients  
 
After ASD subtyping, it is also necessary to 
construct a classification model that can distinguish 
between different ASD subtypes. A wide range of 
supervised learning methods are available to build a 
classifier that is used to predict the subtype of a new 
ASD patient. Since the multi-omics and clinical 
evaluation data are integrated when producing ASD 
subtype clusters, it is also beneficial to improve the 
model performance that integrating different data 
modalities to obtain complementary information when 
building an ASD subtype prediction model. Deep 
learning method is suitable for extracting more 
discriminative features from high-dimensional and 
complex data. The extracted features from each data 
modality then can be integrated to further improve the 
model performance. The ASD subtype prediction 
framework is shown in Figure 2. 
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Convolutional Neural Network (CNN) is a 
feedforward neural network derived from biological 
nerves. It is a multi-layer perceptron model designed to 
recognize two-dimensional images and has certain 
invariance to image transformation. CNN is composed 
of three components including the convolutional layer, 
the pooling layer, and the fully connected layer, and it 
has some advantages such as network weight sharing 
and direct input of the original image. Although CNN 
is mainly used in the field of computer vision, its 
powerful feature analysis capabilities can also be used 
for the processing of biological omics data [28]. There 
are many CNN models such as LeNet-5, Inception v3 
etc. that can be used to extract features from multi-
omics and clinical data.  
Integrating multiple heterogeneous omics data 
sources such as genomic, proteomic, metabolomic, etc. 
can lead to better classification than simply using one 
data source alone. Support Vector Machine (SVM) is a 
supervised learning method and commonly used in 
classification problems. The optimal performance of 
SVMs is highly dependent on the kernel function used. 
Cross validation is the standard approach to select the 
best kernel function among a set of candidates such as 
linear kernel, polynomial kernel and gaussian kernel. 
However, SVM is not suitable for analyzing multiple 
data sources using a single kernel function. We can use 
Multiple Kernel Learning (MKL) method to combine 
kernels calculated on different input data modality to 
obtain better predictive performance [29,30]. 
 
 
 
Figure 2. ASD subtype prediction framework 
 
4. Discussion  
 
The molecular subtyping has been successfully 
applied to cancer research and there are many 
publicly available repositories such as the Cancer 
Genome Atlas (TCGA), Multi-Omics Profiling 
Expression Database (MOPED), Oncomine, 
ArrayExpress, COSMIC etc. In the field of ASD 
research, the National Database for Autism Research 
(NDAR) allows a researcher to associate a single 
research participant’s anonymized genetic, imaging, 
clinical assessment and other information to analyze 
the ASD and its subtypes [31]. This paper proposed 
an ASD subtyping framework based on molecular 
multi-omics data which can be obtained from the 
public databases or from the private medical 
institutions. Unsupervised clustering methods were 
used to fuse the clinical and multi-omics data to 
group them into different clusters. Once the ASD 
subtypes are generated, they can be characterized by 
combining the clusters with existing pathway or 
interaction network knowledge to increase the 
interpretability of the generated ASD subtypes. 
Another framework this paper proposed is the 
classification model to accurately predict the 
subtypes of new ASD patients. In this framework, 
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CNN network was used to extract discriminative 
features from various data modalities. In order to 
differentiate the contributions or weights to the 
classification of each modality, we intended to 
leverage the MKL technique to learn the optimal 
combination coefficients of different kernel functions, 
which is expected to improve the subtype prediction 
accuracy. Of note, there are challenges and 
impediments for ASD subtyping due to data 
heterogeneity, diversity of standards and analysis 
tools, variability of experimental procedures. 
However, compared to ever-changing psychiatric 
nosological definitions such as DSM-5, ASD 
subtyping from molecular perspective holds the 
promise of better personalized healthcare and 
precision medicine for ASD patients with specific 
manifestations.  
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